Nothing Special   »   [go: up one dir, main page]

AU2001236720A1 - Compositions useful as inhibitors of erk - Google Patents

Compositions useful as inhibitors of erk

Info

Publication number
AU2001236720A1
AU2001236720A1 AU2001236720A AU3672001A AU2001236720A1 AU 2001236720 A1 AU2001236720 A1 AU 2001236720A1 AU 2001236720 A AU2001236720 A AU 2001236720A AU 3672001 A AU3672001 A AU 3672001A AU 2001236720 A1 AU2001236720 A1 AU 2001236720A1
Authority
AU
Australia
Prior art keywords
erk
inhibitors
compositions useful
compositions
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001236720A
Inventor
Xiaoling Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of AU2001236720A1 publication Critical patent/AU2001236720A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001236720A 2000-02-05 2001-02-05 Compositions useful as inhibitors of erk Abandoned AU2001236720A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18050200P 2000-02-05 2000-02-05
US60180502 2000-02-05
US19195900P 2000-03-24 2000-03-24
US60191959 2000-03-24
PCT/US2001/003904 WO2001056557A2 (en) 2000-02-05 2001-02-05 Compositions useful as inhibitors of erk

Publications (1)

Publication Number Publication Date
AU2001236720A1 true AU2001236720A1 (en) 2001-08-14

Family

ID=26876382

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001236720A Abandoned AU2001236720A1 (en) 2000-02-05 2001-02-05 Compositions useful as inhibitors of erk

Country Status (5)

Country Link
US (2) US6849267B2 (en)
EP (1) EP1207864A2 (en)
AU (1) AU2001236720A1 (en)
CA (1) CA2369502A1 (en)
WO (1) WO2001056557A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436915B1 (en) 2000-04-07 2002-08-20 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
JP4052573B2 (en) 2000-09-15 2008-02-27 バーテックス ファーマシューティカルズ インコーポレイテッド Isoxazole and its use as an inhibitor of ERK
RU2332996C2 (en) 2001-11-30 2008-09-10 КьюЭлТи Инк. Derivatives of hydrazone-pyraole and medical application theirof
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
ATE389651T1 (en) * 2003-08-15 2008-04-15 Vertex Pharma PYRROLE COMPOSITIONS SUITABLE AS INHIBITORS OF C-MET
CN1870965A (en) * 2003-10-31 2006-11-29 宝洁公司 Method for providing blending composition
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
SE526596C2 (en) 2004-01-13 2005-10-11 Vaelinge Innovation Ab Floating floor with mechanical locking system that allows movement between the floorboards
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
KR20080103996A (en) 2006-02-16 2008-11-28 쉐링 코포레이션 Pyrrolidine derivatives as erk inhibitors
UY30892A1 (en) 2007-02-07 2008-09-02 Smithkline Beckman Corp AKT ACTIVITY INHIBITORS
WO2008138123A1 (en) * 2007-05-09 2008-11-20 Thomas David Y Screening assay to identify correctors of protein trafficking defects
JP5276676B2 (en) 2008-02-21 2013-08-28 メルク・シャープ・アンド・ドーム・コーポレーション Compounds that are ERK inhibitors
NZ621143A (en) * 2008-09-05 2016-08-26 Celgene Avilomics Res Inc Algorithm for designing irreversible inhibitors
BR112012005962A8 (en) 2009-09-16 2018-01-02 Avila Therapeutics Inc PROTEIN KINASE CONJUGATES, COMPOUNDS AND PHARMACEUTICAL COMPOSITION INCLUDING SAID COMPOUNDS
JP2013516422A (en) 2009-12-30 2013-05-13 アビラ セラピューティクス， インコーポレイテッド Protein ligand-directed covalent modification
KR101151715B1 (en) * 2010-01-21 2012-06-15 중앙대학교 산학협력단 Method for Diagnosis of Prostatitis and Kit for the Same
WO2012019113A2 (en) 2010-08-05 2012-02-09 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
US9833439B2 (en) 2011-05-25 2017-12-05 Universite Paris Descartes ERK inhibitors for use in treating spinal muscular atrophy
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
US10864179B2 (en) 2015-10-01 2020-12-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma
WO2017099591A1 (en) 2015-12-07 2017-06-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment of inhibitor resistant braf-mutant cancers
WO2017204626A1 (en) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination therapy - combined map2k4/map3k1 and mek/erk inhibition
WO2020192750A1 (en) 2019-03-28 2020-10-01 江苏恒瑞医药股份有限公司 Thienoheterocyclic derivative, preparation method therefor and medical use thereof
EP3950690A4 (en) 2019-03-29 2022-12-07 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pyrroloheterocyclic derivative, preparation method therefor, and application thereof in medicine
EP3978498A1 (en) 2019-05-24 2022-04-06 Jiangsu Hengrui Medicine Co., Ltd. Substituted fused bicyclic derivative, preparation method therefor, and application thereof in medicines
AU2021354821A1 (en) 2020-09-29 2023-06-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystal form of pyrrolo heterocyclic derivative and preparation method therefor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
IL132736A0 (en) * 1997-05-22 2001-03-19 Searle & Co 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
EP1019394A1 (en) * 1997-05-22 2000-07-19 G.D. Searle & Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
EP1196390A2 (en) * 2000-02-05 2002-04-17 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
WO2002088097A1 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof

Also Published As

Publication number Publication date
US20030049820A1 (en) 2003-03-13
US20040048861A1 (en) 2004-03-11
US6849267B2 (en) 2005-02-01
EP1207864A2 (en) 2002-05-29
WO2001056557A3 (en) 2002-04-04
WO2001056557A2 (en) 2001-08-09
US6994868B2 (en) 2006-02-07
CA2369502A1 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
AU2001236720A1 (en) Compositions useful as inhibitors of erk
HUP0202332A2 (en) Pyrazole compositions useful as inhibitors of erk
AU2003286711A1 (en) Indazolinone compositions useful as kinase inhibitors
AU2001258771A1 (en) -secretase inhibitors
AU2002219418A1 (en) Compositions of estrogen-cyclodextrin complexes
AU2002220265A1 (en) Compositions for inhibiting grb7
AU2001244399A1 (en) Gamma-secretase inhibitors
HK1039110A1 (en) Novel compounds and compositions as protease inhibitors
AU2001253255A1 (en) Compositions and methods for inhibiting gene expression
AU2001245764A1 (en) Novel compounds and compositions as protease inhibitors
AU1530001A (en) Inhibitor compositions
AU2002317374A1 (en) Storage of liquid compositions
AU6381701A (en) Bisamidino compounds as nhe-3 inhibitors
AU2002256543A1 (en) Compositions containing heteropolymers and methods of using same
AU2001270200A1 (en) Fatty acid synthase inhibitors
AU2001296515A1 (en) Cyclic sulfonyl compounds as inhibitors of metalloproteases
AU2002304853A1 (en) Substituted benzopyranones as telomerase inhibitors
AU2001280721A1 (en) Compositions of iodonium compounds and methods and uses thereof
AU2001281059A1 (en) Fatty acid synthase inhibitors
AU2002241211A1 (en) Imidazo-triazine derivatives as pde 5 inhibitors
AU2001255408A1 (en) Tetrahydro-azepinone derivatives as thrombin inhibitors
AU2002214038A1 (en) Inhibitors of transglutaminases
AU2001271531A1 (en) Fatty acid synthase inhibitors
AUPQ644900A0 (en) Preserving compositions
AU2002243439A1 (en) Fatty acid synthase inhibitors